On 29 November, Shanghai-based Full-Life Technologies Limited announced it would acquire Focus-X Therapeutics, a two-year-old US biotech focusing on the development of peptide receptor radionuclide therapies.
The Chinese biotech is expanding into the radiopharmaceutical arena and its first foreign acquisition in the field is worth up...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

